OTREXUP - (10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML)

Generic Name	METHOTREXATE	**Innovator**	ASSERTIO Therapeutics
Dosage	10MG/0.4ML, 15MG/0.4ML, 20MG/0.4ML, 25MG/0.4ML, 7.5MG/0.4ML, 12.5MG/0.4ML, 17.5MG/0.4ML, 22.5MG/0.4ML	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	Otrexup is a folate analog metabolic inhibitor indicated for the: • Management of patients with severe, active rheumatoid arthritis (RA) and polyarticular juvenile idiopathic arthritis (pJIA), who are intolerant of or had an inadequate response to first-line therapy. • Symptomatic control of severe, recalcitrant, disabling psoriasis in adults who are not adequately responsive to other forms of therapy.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Address: G4 Sani Apt., Subhanpura, Vadodara, Gujarat, India - 390 023
Tel: +91.9909919584 | E-mail: contact@researchdelta.com | Website: www.researchdelta.com